Skip to main content
NCBI home page
Springer logoLink to Springer
. 2021 Feb 18;113(4):611. doi: 10.1007/s12185-021-03091-0

Correction to: Safety profile of brentuximab vedotin in Japanese patients with relapsed/refractory Hodgkin lymphoma or systemic anaplastic large cell lymphoma: a post-marketing surveillance study

Koji Izutsu 1,2, Michinori Ogura 3, Kensei Tobinai 1, Kiyohiko Hatake 4,5, Shigeru Sakamoto 6, Masanori Nishimura 7, Miyako Hoshino 6,✉
PMCID: PMC8329798  PMID: 33604778

Correction to: International Journal of Hematology 10.1007/s12185-020-03039-w

In the original publication of the article, the affiliation of the corresponding author “Miyako Hoshino” should be changed to “Japan Medical Office, Japan Pharma Business Unit, Takeda Pharmaceutical Co. Ltd., 1‑1, Nihonbashi‑Honcho 2‑chome, Chuo‑ku, Tokyo 103‑8668, Japan”.

Footnotes

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Articles from International Journal of Hematology are provided here courtesy of Springer

RESOURCES